CTS

CTS is a well-run, financially sound maker of sensing/connectivity/motion components for aerospace & defense, medical, industrial and transportation OEMs. FY2025 was a strong operating year: revenue +5.2% to $541M, but the real story is profitability — gross margin expanded 200bps to 38.4% and operating margin rose to 15.3% from 13.8% on 'continued operational improvements and an improved mix,' driving net income +17.7% to $65.3M and diluted EPS +21% to $2.19. The balance sheet is a clear strength: liabilities/equity of just 0.39x, $82.3M cash against only $57.5M drawn on the revolver (net cash), $102M operating cash flow against $15.7M capex (~$86M free cash flow), and a 4.5% reduction in share count from $56.2M of buybacks. This is a quality compounder profile, not a distressed one.

The caution is twofold. First, revenue durability is questionable. The five-year history is lumpy and uninspiring — $587M (2022), $550M (2023), $515M (2024), $541M (2025) — meaning 2025 sales are still below the 2022 peak, and even the 2025 gain leaned on the SyQwest acquisition (+$22.3M, vs. only $13.4M in 2024, so ~$9M of organic acquisition tailwind) plus a 16.3% jump in diversified end markets. The transportation segment, a core franchise, fell 6.6% on lower commercial-vehicle volumes and 'our customers' loss of market share in China' — a structural, not transitory, headwind. Much of the EPS growth therefore came from margin expansion and a shrinking share count rather than top-line momentum, and both levers have limits. Note also that SG&A rose faster than sales (18.2% vs 17.2% of sales), partly on a one-time EPA settlement charge and SyQwest amortization.